The antimutagenicity of 2-substituted selenazolidine-4-(R)-carboxylic acids.

The antimutagenicity of 2-substituted selenazolidine-4-(R)-carboxylic acids. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

The antimutagenicity of 2-substituted selenazolidine-4-(R)-carboxylic acids. Abstract Text:

Wael M El-Sayed,Warda A Hussin,Michael R Franklin,

Selenium can have cancer chemopreventive activity, although the mechanism of action has not been well defined. Selenazolidine-4-(R)-carboxylic acids (SCAs) were devised as prodrugs of L-selenocysteine, to provide selenium in a form and at a concentration commensurate with cancer chemopreventive activity. In the present study, a series of selenazolidines has been evaluated in the Salmonella typhimurium TA98 tester strain and all were found to possess antimutagenic activity. There was little difference between the seven selenazolidines in their effectiveness against either benzo[a]pyrene (B[a]P) or 3,6-bis(dimethylamino)acridine (acridine orange), agents which differ in their requirement for mammalian enzyme bioactivation for mutagenicity. Antimutagenic activity against acridine orange was dependent on selenazolidine concentration, and EC50 values were in the 5-10 microM range. At 25 microM, the concentration tested in common for the two mutagens, the selenazolidines were more effective antimutagens against acridine orange than against B[a]P, with reductions in mutant frequency ranging from 54 to 71% for B[a]P and 79 to 93% for acridine orange. Efficacy against B[a]P was not enhanced when the concentration was increased to 50 microM. The similarity in efficacy among the selenazolidines against B[a]P mutagenicity, contrasted with inter-compound differences in their ability to inhibit S9 CYP1A activity. The CYP1A Ki values ranged from a low of 63 microM (2-[2'-hydroxyphenyl]SCA) to a high of 1.1mM (2-cyclohexylSCA), but all were above the concentration required to inhibit mutagenicity by 50%. Thus, all the SCAs possess antimutagenic activity against both B[a]P and acridine orange, the efficacy varies little between the individual selenazolidines, and for B[a]P, the efficacy is not proportional to the inhibitory effect on the mutagen bioactivating enzyme.

The antimutagenicity of 2-substituted selenazolidine-4-(R)-carboxylic acids. Publishing Authors By Initials

WM El-Sayed,WA Hussin,MR Franklin,

For similar bacteria: gram-negative bacteria: gram-negative facultatively anaerobic rods: enterobacteriaceae: salmonella: salmonella enterica: salmonella typhimurium research abstracts see: bacteria: gram-negative bacteria: gram-negative facultatively anaerobic rods: enterobacteriaceae: salmonella: salmonella enterica: salmonella typhimurium research

PUBMED ID PMID:

MEDLINE DATE:

The antimutagenicity of 2-substituted selenazolidine-4-(R)-carboxylic acids. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Mutation research

VOLUME: 627

Page Numbers: 136-45

Journal Abbreviation: Mutat. Res.

ISSN: 0027-5107

DAY: 12

MONTH: 12

YEAR: 2006

The antimutagenicity of 2-substituted selenazolidine-4-(R)-carboxylic acids. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 400763

The antimutagenicity of 2-substituted selenazolidine-4-(R)-carboxylic acids. Keywords Mesh Terms:

KEYWORDS: Salmonella typhimurium

MESH TERMS: genetics

Chemical & Substance for Abstract: The antimutagenicity of 2-substituted selenazolidine-4-(R)-carboxylic acids. Information

Substance Name: Cytochrome P-450 CYP1A1

Registry Number: EC 1.14.14.1

Grant and Affiliation Information for The antimutagenicity of 2-substituted selenazolidine-4-(R)-carboxylic acids.

AFFILIATION: University of Utah, Department of Pharmacology and Toxicology, Salt Lake City, UT 84112, USA.

Country: Netherlands

AGENCY: United States NIGMS

GRANT: R01 GM058913-06

ACRONYM: GM

MEDLINETA: Mutat Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

The antimutagenicity of 2-substituted selenazolidine-4-R-carboxylic acids Related Publications

• 'Crook' pipettes: embryonic emigrations from agriculture to reproductive biomedicine.
• 145.
• Appropriateness of Exercise Testing in Asymptomatic Men and Women: Improved Clinical Outcomes?: 73: 2:10 PM-2:40 PM.
• Bax affects production of reactive oxygen by the mitochondria of non-apoptotic neurons.
• Breeding colony refinement through phenotypic and genotypic characterization of the SPRD-Pkdr1/Rrrc rat model of polycystic kidney disease.
• Cardiologists' Perception of Secondary Prevention and Cardiac Rehabilitation Referral Patterns: Influence of Personal Lifestyle Practices: 1724: Board #12 May 31 9:00 AM - 10:30 AM.
• Cardiorespiratory fitness in older adults referred for diagnostic exercise testing: modulating variables: 2385: board #64 june 1 2:00 PM -3:30 PM.
• Characterization of cecal gene expression in a differentially susceptible mouse model of bacterial-induced inflammatory bowel disease.
• Cognitive behavioral treatment for young children with obsessive-compulsive disorder.
• Comparative phylogeography and genetic structure of Vanuatu birds: control region variation in a rail, a dove, and a passerine.
• Conventional Screening Guidelines: 127: 3:20 PM-3:45 PM.
• Dietary behaviors and knowledge among urban pre-adolescents: 1581: board #71 may 30 3:30 PM - 5:00 PM.
• Dose-response relationships between vigorous exercise and prevalence of diabetic, hypertensive, and hypercholesterolemia medication use: 709: may 31 1:30 PM 1:45 PM.
• EGFR-mutant lung adenocarcinoma in a patient with Li-Fraumeni syndrome.
• Effect of metabolic inhibitors on ATP and citrate content in PC3 prostate cancer cells.
• Energy Expenditure, Epicardial Adipose Tissue and Cardiorespiratory Fitness in Morbidly Obese Adults: 2154: Board #67 June 1 8:00 AM - 9:30 AM.
• Function and Mortality in Coronary Patients: Cardioprotective Mechanisms: 207: 1:45 PM-2:15 PM.
• Influence of a High-Intensity Resistance Training Program on Muscular Strength in Coronary Patients: 1731: Board #19 May 31 9:00 AM 10:30 AM.
• Introduction and Overview: 70: 1:00 PM-1:10 PM.
• Lifestyle Activity in Patients Engaged in Phase 3 Cardiac Rehabilitation: Scheduled Versus Non-Scheduled Exercise Days: 1733: Board #21 May 31 9:00 AM 10:30 AM.
• Murine hepatoma (Hepa1c1c7) cells: a responsive in vitro system for chemoprotective enzyme induction by organoselenium compounds.
• Prognostic factors of long-term disability in a workers' compensation system.
• Reactive oxygen intermediates and signaling through kinase pathways.
• Reactive oxygen species-induced activation of the MAP kinase signaling pathways.
• Resistance Training-Induced Attenuation of the Hemodynamic Responses to Standardized Lifting in Coronary Patients: 657: May 31 9:45 AM 10:00 AM.
• Supine and prone stress myocardial perfusion imaging in women evaluated for suspected coronary artery disease: 2390: board #69 june 1 2:00 PM -3:30 PM.
• The antimutagenicity of 2-substituted selenazolidine-4-(R)-carboxylic acids.
• Traumatic and socially stressful life events among persons with social anxiety disorder.
• Tumor cell metabolism: the marriage of molecular genetics and proteomics with cellular intermediary metabolism; proceed with caution!
• Use of VE/VCO2 slope Corrected for Peak VO2 as a Predictor of Post-Surgical Complications in Morbidly Obese Patients: 686: May 31 8:30 AM 8:45 AM.